NASDAQ: AZRX

SEARCH

SIGN UP

AzurRx Logo
  • About
      • Back
      • Company Profile
      • Management Team
      • Board of Directors
      • Scientific Advisory Board
  • Science & Technology
      • Back
      • Overview
      • Programs
      • Development Pipeline
      • Cystic Fibrosis
      • Chronic Pancreatitis
      • Immune Checkpoint Inhibitor Colitis
      • COVID-19 GI Infections
      • Non-Systemic Biologics
      • Digestive Enzymes
      • Niclosamide
  • Investors
      • Back
      • Press Releases
          • Back
          • 2021
          • 2020
          • 2019
          • 2018
          • 2017
          • 2016
          • 2015
          • 2014
      • Events
      • Presentations
      • Regulatory Filings
      • Financial Statements
          • Back
          • 2020
              • Back
              • Q2 2020
              • Q1 2020
          • 2019
              • Back
              • Q4 2019
              • Q3 2019
              • Q2 2019
              • Q1 2019
          • 2018
              • Back
              • Q4 2018
              • Q3 2018
              • Q2 2018
              • Q1 2018
          • 2017
              • Back
              • Q4 2017
              • Q3 2017
              • Q2 2017
              • Q1 2017
          • 2016
              • Back
              • Q4 2016
              • Q3 2016
      • Stock Info
      • Analyst Coverage
      • Corporate Governance
      • Contact Us
  • News and Media
      • Back
      • Podcasts
      • Media Interviews
  • Clinical Trials
      • Back
      • Ongoing Clinical Trials
      • Completed Clinical Trials
      • Clinical Publications
  • Collaborations
      • Back
      • Partnering with AzurRx
  • Contact
      • Back
      • Contact Us
      • Subscribe
  • Home
  • Investors
  • Press Releases
  • 2021

Menu

  • Press Releases
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
  • Events
  • Presentations
  • Regulatory Filings
  • Financial Statements
    • 2020
      • Q2 2020
      • Q1 2020
    • 2019
      • Q4 2019
      • Q3 2019
      • Q2 2019
      • Q1 2019
    • 2018
      • Q4 2018
      • Q3 2018
      • Q2 2018
      • Q1 2018
    • 2017
      • Q4 2017
      • Q3 2017
      • Q2 2017
      • Q1 2017
    • 2016
      • Q4 2016
      • Q3 2016
  • Stock Info
  • Analyst Coverage
  • Corporate Governance
  • Contact Us

2021 News

Filters
List of articles in category 2021 News
Title Date
AzurRx BioPharma to Participate in “Fireside Chat” at the H.C. Wainwright Global Life Sciences Conference 02 Mar, 2021
AzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of Directors 24 Feb, 2021
AzurRx BioPharma to Present at The Microcap Rodeo Winter Wonderland Conference 16 Feb, 2021
AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections 09 Feb, 2021
AzurRx BioPharma to Present at BIO CEO & Investor Digital Conference 08 Feb, 2021
AzurRx BioPharma Announces Completion of Enrollment in First Cohort of Phase 2b OPTION 2 Extension Study of MS1819 28 Jan, 2021
AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients 26 Jan, 2021
AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients 21 Jan, 2021
AzurRx BioPharma and First Wave Bio Announce Allowance of U.S. Patent Application for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections 12 Jan, 2021
AzurRx BioPharma CEO Issues Letter to Shareholders 08 Jan, 2021
AzurRx BioPharma to Participate in Biotech Showcase Digital 2021 Conference 07 Jan, 2021
AzurRx BioPharma to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference 06 Jan, 2021
AzurRx BioPharma to Participate in 10th Annual LifeSci Partners Corporate Access Event 05 Jan, 2021
AzurRx BioPharma Announces $8.0 Million Offerings 04 Jan, 2021
AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections 04 Jan, 2021
  • About
  • Science & Technology
  • Investors
  • News and Media
  • Clinical Trials
  • Collaborations
  • Contact

Contact Us

AzurRx BioPharma, Inc.

1615 South Congress Avenue
Suite 103
Delray Beach, Florida 33445 

Tel: 646-699-7855
info@azurrx.com

AzurRx SAS

Jardin des Entreprises, Bat 1
290, Chemin de Saint-Dionisy
30980 Langlade, France

Tel: +33 (0)4 66 67 08 16

SiteMap Ⓒ 2021 AzurRx All Rights Reserved.